Is Your 340B Vendor A Partner Or A Parasite?

May 16, 2024340B, Covered Entities, Patient Eligibility, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy

Why 340B vendors charging Percentage Of Revenue is wrong. The United States Congress established the 340B statute in 1992 to help non-profit hospitals fill-in the often-backbreaking revenue gaps inherent to their business models — enabling covered entities to replenish eligible prescriptions at significant savings. Savings which they can then pass-along to their patients, many of … Read More

340B Outlook For 2024: Change. Change. And More Change.

April 19, 2024340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, News Updates, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

What we’ve learned. What it means for your 340B program. Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. In spite of the drug manufacturer restrictions that have devastated many hospitals’ programs, every … Read More

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

April 4, 2024340B, 340B ESP, Bedside Prescription Delivery, Compliance, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, Prescription Discounts, Requirements, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy

Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. According to a report by The American Hospital Association, the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase … Read More

The Best 340B Program Is More Than Just A 340B Program. Much More.

March 12, 2024340B, Bedside Prescription Delivery, Contract Pharmacy, Drug Manufacturer Restrictions, Meds To Beds, Specialty Drugs, Specialty Pharmacy, TPA / TPAs

Congress established the 340B program in 1992 to help non-profit hospitals fill-in the significant revenue gaps inherent to their business models. What the bill’s supporters did not foresee, and what very few eligible health systems realize — even today — is that 340B can function as the central hub of a multi-point program. One that … Read More

Leveraging Partnerships With Drug Manufacturers To Overcome 340B Restrictions On Specialty Drugs

March 1, 2024340B, 340B ESP, Bedside Prescription Delivery, Drug Manufacturer Restrictions, Medicare, Meds To Beds, PBM, Specialty Drugs, Specialty Drugs, Specialty Pharmacy

It’s no secret that the 340B Drug Pricing Program has been a lifeline for eligible health systems, enabling them to fill-in the massive revenue gaps inherent to the non-profit-hospital business model (and, in the process, support their mission of providing quality care to our nation’s most vulnerable patients) through access to discounted prescription refills. At … Read More

Your Hospital’s 340B Contract Pharmacy Network Is Not What It Should Be.

February 15, 2024340B, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Patient Eligibility, PBM, Prescription Discounts, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs, Uncategorized

Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. Altogether, we’ve generated more than $500 million in 340B Savings and Revenue for those health systems — $98M in the first 10 months … Read More

The 2023 Guide To Implementing An Effective 340B Program

May 24, 2023340B, 340B ESP, Bedside Prescription Delivery, Compliance, Covered Entities, Drug Manufacturer Restrictions, Meds To Beds, PBM, Requirements, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities (the 340B basics, if you will) remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — … Read More

Why 340B Hospitals Should Now Build Their Own Specialty Pharmacies

May 3, 2023340B, 340B ESP, Covered Entities, Drug Manufacturer Restrictions, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post, for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialty pharmacy offers enormous savings and revenue potential. Some covered entities generate as much as 600% in specialty pharmacy revenue from 340B drugs as they … Read More

Seven Steps For Overcoming 340B ESP and Other Manufacturer Restrictions on 340B Pricing

December 20, 2022340B, 340B ESP, Contract Pharmacy, Covered Entities, Requirements, Specialty Drugs, Specialty Pharmacy

ProxsysRx’s process for recovering lost 340B savings and revenue As we’ve noted in multiple earlier blog posts, 340B ESP is nothing short of a blatant, lawless tactic used by scores of drug manufacturers to disallow the discounts they are legally obligated to offer eligible entities. At the same time, a number of additional manufacturers are … Read More

340B Outlook For 2024: Change. Change. And More Change.

October 4, 2021340B, 340B ESP, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs

What we’ve learned. What it means for your 340B program. Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. In spite of drug manufacturer restrictions, every one of the 13 health systems we … Read More